|
| Home : Talisman Energy Inc. Announces Latest Results of Its Debt Tender Offer, Increase to the Maximum Tender Amount, and Extension of Expiration Date |
|
Dec 24
2015 |
Talisman Energy Inc. Announces Latest Results of Its Debt Tender Offer, Increase to the Maximum Tender Amount, and Extension of Expiration Date |
|
CALGARY, ALBERTA--(Marketwired - Dec. 23, 2015) - Talisman Energy Inc. (the "Offeror") announced today the results, as of the Prior Expiration Date (as defined below), of its previously announced tender offer (the "Offer") to purchase for cash for a combined aggregate principal amount of up to $1,524,531,000 (the "Maximum Tender Amount") of the 5.85% Senior Notes due 2037 (CUSIP No. 87425E AJ2), 5.50% Senior Notes due 2042 (CUSIP No. 87425E AN3), 6.25% Senior Notes due 2038 (CUSIP No. 87425E AK9), 7.25% Debentures due 2027 (CUSIP No. 87425E AE3) and 5.75% Senior Notes due 2035 (CUSIP No. 87425E AH6) issued by the Offeror (collectively, the "Securities"). In addition, the Offeror announced the following further amendments to the Offer: (i) it has raised the Maximum Tender Amount to $2,000,000,000, (ii) it has extended the Expiration Date from 12:00 midnight, New York City time, on December 22, 2015 (one minute after 11:59 p.m., New York City time, on December 22, 2015) (the "Prior Expiration Date") to 12:00 midnight, New York City time, on January 7, 2016 (one minute after 11:59 p.m., New York City time, on January 7, 2016) (as it may be extended or earlier terminated, the "Expiration Date"), and (iii) it has established a new Interim Settlement Date (as defined below). |
|
|
|
| Source:http://www.marketwired.com/mw/release.do?id=2084338&sourceType=3 |
| |
|
Related News
|
» Cadillac Announces Conditional TSXV Approval for $150,000 Debenture Financing
» Qu Biologics Closes Oversubscribed Financing; Crohn's Disease Phase 2 Clinical Trial Results in First Quarter 2016
|
|
|
